Initiation of insulin therapy in patients with type 2 diabetes: An observational study

Acta Pharm. 2021 Aug 30;72(1):147-157. doi: 10.2478/acph-2022-0011. Print 2022 Mar 1.

Abstract

The aim of the study was to assess the initiation of insulin therapy in patients with type 2 diabetes using health claims data on prescription medicines. The study evaluated time to insulin initiation and prescribing patterns of other anti-diabetic medicines before and after insulin initiation. Five years after starting non-insulin antidiabetic therapy, 6.4 % of patients were prescribed insulin, which is substantially lower compared to other similar studies. Among all patients who initiated insulin therapy in 2013, 30 % did not continue any other antidiabetic therapy. However, this proportion was lowered to 20 % in 2018. Before insulin initiation in 2018, metformin was prescribed in only 67 % of patients and sulfonylureas in 78 % of patients. Moreover, metformin and sulfonylureas were discontinued after insulin initiation in 26 and 37 % of patients, resp. More attention should be paid to the continuation of oral anti-diabetics, particularly metformin, after insulin initiation.

Keywords: diabetes mellitus; insulin; metformin; sulfonylurea.

Publication types

  • Observational Study

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Metformin* / therapeutic use
  • Sulfonylurea Compounds / therapeutic use

Substances

  • Insulin
  • Hypoglycemic Agents
  • Metformin
  • Sulfonylurea Compounds